ORKA General Counsel Paul Quinlan Sells $51K of Stock

Insider Buying and Selling at Oruka Therapeutics, Inc.

On June 15, 2026, Paul Quinlan, the General Counsel of Oruka Therapeutics, Inc. (NasdaqGM: ORKA), sold 733 shares at a price of $69.69 each. This transaction was valued at approximately $51,082. The sale comes as the stock is currently trading at $68.86, showing a decline from its previous close of $94.96.

Other Insider Transactions

This sale by Quinlan adds to a series of recent insider activities at Oruka. On the same day, CEO Lawrence Otto Klein sold 1,729 shares at the same price, totaling about $120,494. Additionally, Chief Operating Officer Sandler Laura Lee sold 600 shares for $41,814. Senior Vice President of Finance Arjun Agarwal also sold 395 shares, while he had previously purchased 9,459 shares just days before on June 12. These transactions highlight ongoing trading among Oruka's leadership.

Stock Performance and Market Context

Oruka Therapeutics shares have experienced some volatility, trading significantly lower than their 52-week high of $115.52. The stock's recent performance, trading around $68.86, is concerning for investors, especially following the notable insider selling activity. The stock is well below its 50-day moving average of $96.42, which may signal caution among market participants.

Analysts Set New Price Targets

Despite recent insider selling, analysts remain bullish on Oruka Therapeutics. On September 24, 2026, Wedbush reiterated its 'Outperform' rating with a price target of $165, while HC Wainwright & Co. also maintained a 'Buy' rating with a target of $120. The consensus among 12 analyst opinions suggests a strong buy recommendation, with a mean price target of $155, indicating confidence in the company's future prospects.

What Oruka Therapeutics, Inc. Does

Oruka Therapeutics, Inc., based in Menlo Park, California, focuses on developing innovative monoclonal antibody therapies for psoriasis and other inflammatory conditions. Its lead products are currently in various stages of clinical trials, which could significantly impact its market position moving forward.

What to Watch at Oruka Therapeutics, Inc.

Investors will be looking ahead to Oruka's next earnings report scheduled for November 11, 2026. It's important to note that the insider transactions reported here reflect past activity and may not represent current holdings, as these filings are backward-looking. The ongoing trading activity among insiders and the outlook from analysts will be key factors to monitor in the coming weeks.